What is CME Group Inc.'s earnings per share (EPS)?

CME Group Inc. (CME) reported diluted earnings per share of $11.16 for fiscal year 2025. This represents a 15.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

CME Group Inc. (CME) Financials

CME

Trailing 12 months to June 30, 2026

Revenue $6.8B +5.1% YoY

Net Income $4.3B +13.8% YoY

EPS (Diluted) $11.79 +14.1% YoY

Free Cash Flow $4.2B +2.6% YoY

Market Cap $100.9B as of Oct 10, 2026

Price / Sales 14.9x on $6.8B revenue, trailing 12 months to June 30, 2026

Price / Earnings 23.5x on $4.3B net income, trailing 12 months to June 30, 2026

Price / Book 3.8x on $26.5B equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Jul 24, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Jul 24, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CME SEC filings page.

CME Group Inc. (CME) reported $6.8B in revenue over the twelve months to Jun 30, 2026, up 5.1% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CME FY2025 2026-10-03

CME's cash conversion requires little reinvestment, but its liability-heavy balance sheet makes leverage central to understanding the business.

The cash figures tell a higher-quality story than earnings alone: FY2025 operating cash flow was $4.3B and free cash flow was $4.2B, showing that reported profits largely became cash. With capital expenditures of only $84M, the narrow gap reflects a lightly reinvestment-heavy model rather than substantial fixed-asset spending.

Assets expanded to $198.4B from $137.4B in FY2024, but that scale is not equivalent to shareholder capital. Liabilities reached $169.7B, while debt-to-equity rose to 5.9x, making balance-sheet structure more important than the income statement alone suggests.

Operating margin advanced from 61.6% in FY2023 to 64.9% in FY2025. That widening indicates that a greater share of incremental revenue reached operating income, although the reported figures cannot separate scale effects from changes in mix or costs.

Financial Health Signals

Financial Health Score 60/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of CME Group Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

CME Group Inc. has an operating margin of 64.9%, meaning the company retains $65 of operating profit per $100 of revenue. This strong profitability earns a score of 99/100, reflecting efficient cost management and pricing power. This is up from 64.1% the prior year.

Growth

CME Group Inc.'s revenue grew 6.4% year-over-year to $6.5B, a solid pace of expansion. This earns a growth score of 60/100.

Leverage

CME Group Inc. has elevated debt relative to equity (D/E of 5.91), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 9/100, reflecting increased financial risk.

Liquidity

CME Group Inc.'s current ratio of 1.03 is below the typical benchmark, resulting in a score of 20/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Cash Flow

CME Group Inc. converts 64.3% of revenue into free cash flow ($4.2B). This strong cash generation earns a score of 99/100.

Returns

CME Group Inc. earns a strong 14.2% return on equity (ROE), meaning it generates $14 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 75/100. This is up from 13.3% the prior year.

Altman Z-Score Distress

0.54

CME Group Inc. scores 0.54, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($100.9B) relative to total liabilities ($169.7B). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

4/6

CME Group Inc. passes 4 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 3 of 4 profitability signals pass, all 1 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Cash-Backed

1.05x

For every $1 of reported earnings, CME Group Inc. generates $1.05 in operating cash flow ($4.3B OCF vs $4.1B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

24.39x

CME Group Inc. earns $24.39 in operating income for every $1 of interest expense ($4.2B vs $173.4M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$1.7B

YoY+0.8%

QoQ-9.2%

5Y CAGR+7.7%

10Y CAGR+6.5%

CME Group Inc. generated $1.7B in revenue in Q2 2026. This represents an increase of 0.8% from the same quarter a year earlier. Against the prior quarter it is down 9.2%.

EBITDA

$1.2B

YoY-1.8%

QoQ-14.5%

5Y CAGR+9.1%

CME Group Inc.'s EBITDA was $1.2B in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 1.8% from the same quarter a year earlier. Against the prior quarter it is down 14.5%.

Net Income

$1.0B

YoY+1.6%

QoQ-9.7%

5Y CAGR+15.3%

10Y CAGR+12.5%

CME Group Inc. reported $1.0B in net income in Q2 2026. This represents an increase of 1.6% from the same quarter a year earlier. Against the prior quarter it is down 9.7%.

EPS (Diluted)

$2.88

YoY+2.5%

QoQ-9.4%

5Y CAGR+15.2%

10Y CAGR+11.7%

CME Group Inc. earned $2.88 per diluted share (EPS) in Q2 2026. This represents an increase of 2.5% from the same quarter a year earlier. Against the prior quarter it is down 9.4%.

Cash & Balance Sheet

Free Cash Flow

$923.5M

YoY-11.2%

QoQ-25.4%

5Y CAGR+15.0%

10Y CAGR+16.3%

CME Group Inc. generated $923.5M in free cash flow in Q2 2026, representing cash available after capex. This represents a decrease of 11.2% from the same quarter a year earlier. Against the prior quarter it is down 25.4%.

Cash & Debt

$2.1B

YoY+8.2%

QoQ-10.3%

5Y CAGR+14.7%

10Y CAGR+6.3%

CME Group Inc. held $2.1B in cash as of Q2 2026; long-term debt is not reported for that period.

Dividends Per Share

$1.30

YoY+4.0%

QoQ-82.6%

CME Group Inc. paid $1.30 per share in dividends in Q2 2026. This represents an increase of 4.0% from the same quarter a year earlier. Against the prior quarter it is down 82.6%.

Shares Outstanding

Diluted avg 361M

CME Group Inc. had a weighted average of 361M diluted shares in Q2 2026; the shares outstanding count is not reported for that period.

Margins & Returns

Operating Margin

64.9%

YoY-1.8pp

QoQ-4.8pp

5Y change+7.7pp

10Y change+2.7pp

CME Group Inc.'s operating margin was 64.9% in Q2 2026, reflecting core business profitability. This is down 1.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 4.8 percentage points.

Net Margin

61.1%

YoY+0.5pp

QoQ-0.3pp

5Y change+17.8pp

10Y change+25.7pp

CME Group Inc.'s net profit margin was 61.1% in Q2 2026, showing the share of revenue converted to profit. This is up 0.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.3 percentage points.

Return on Equity

3.9%

YoY+0.2pp

QoQ-0.4pp

5Y change+2.0pp

10Y change+2.4pp

CME Group Inc.'s ROE was 3.9% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 0.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.4 percentage points.

Gross Margin

Not reported for Q2 2026.

Capital Allocation

Capital Expenditures

$23.6M

YoY+28.3%

QoQ+8.3%

5Y CAGR-9.9%

10Y CAGR+2.0%

CME Group Inc. invested $23.6M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 28.3% from the same quarter a year earlier. Against the prior quarter it is up 8.3%.

R&D Spending

Not reported for Q2 2026.

Share Buybacks

Not reported for Q2 2026.

CME Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CME quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$6.8B	$6.5B+6.4%	$6.1B+9.9%	$5.6B+11.1%	$5.0B+7.0%	$4.7B-4.0%	$4.9B+0.3%	$4.9B+13.0%	$4.3B+18.2%	$3.6B+1.4%	$3.6B+8.1%	$3.3B+6.9%	$3.1B+6.0%	$2.9B+0.7%	$2.9B-11.2%	$3.3B
SG&A Expenses	$935.2M	$907.0M+6.7%	$850.3M+2.6%	$828.6M+10.0%	$753.1M-10.0%	$837.0M-2.3%	$856.5M-4.7%	$898.7M+33.7%	$672.2M+19.2%	$563.9M+3.8%	$543.2M-1.9%	$553.7M+0.3%	$552.1M+6.4%	$518.9M+4.5%	$496.7M+4.4%	$475.7M
Operating Income	$4.4B	$4.2B+7.6%	$3.9B+14.4%	$3.4B+13.9%	$3.0B+14.0%	$2.6B+0.3%	$2.6B+1.9%	$2.6B-0.8%	$2.6B+12.9%	$2.3B+5.0%	$2.2B+10.7%	$2.0B+12.5%	$1.8B+8.0%	$1.6B-3.3%	$1.7B-16.3%	$2.0B
EBITDA	N/A	$4.3B+7.2%	$4.0B+13.6%	$3.6B+13.0%	$3.2B+12.8%	$2.8B+0.1%	$2.8B+1.6%	$2.7B+0.7%	$2.7B+12.5%	$2.4B+4.0%	$2.3B+10.0%	$2.1B+11.4%	$1.9B+7.3%	$1.8B-3.1%	$1.8B-14.9%	$2.1B
Interest Expense	$174.9M	$173.4M+7.8%	$160.9M+0.9%	$159.4M-2.0%	$162.7M-2.5%	$166.9M+0.4%	$166.2M-6.6%	$178.0M+12.9%	$157.7M+34.8%	$117.0M-5.3%	$123.5M+5.2%	$117.4M-1.7%	$119.4M-21.1%	$151.4M+14.5%	$132.2M+13.1%	$116.9M
Income Tax	$1.3B	$1.3B+23.9%	$1.0B+9.5%	$927.4M+16.0%	$799.3M+8.5%	$736.7M+19.7%	$615.7M+7.3%	$573.8M-29.5%	$814.1M+153.0%	-$1.5B-304.0%	$753.5M+6.2%	$709.8M+10.1%	$644.5M+3.5%	$622.9M-20.8%	$786.7M+544.3%	$122.1M
Net Income	$4.3B	$4.1B+15.5%	$3.5B+9.3%	$3.2B+19.9%	$2.7B+2.0%	$2.6B+25.2%	$2.1B-0.5%	$2.1B+7.9%	$2.0B-51.7%	$4.1B+164.9%	$1.5B+23.0%	$1.2B+10.6%	$1.1B+15.4%	$976.8M+9.0%	$896.3M-50.5%	$1.8B
EPS (Basic)	N/A	$11.18+15.4%	$9.69+9.2%	$8.87+19.7%	$7.41+1.5%	$7.30+24.1%	$5.88-0.8%	$5.93+3.5%	$5.73-52.3%	$12.00+163.7%	$4.55+22.6%	$3.71+10.1%	$3.37+14.6%	$2.94+8.5%	$2.71-50.3%	$5.45
EPS (Diluted)	$11.79	$11.16+15.4%	$9.67+9.1%	$8.86+19.7%	$7.40+1.5%	$7.29+24.2%	$5.87-0.7%	$5.91+3.5%	$5.71-52.2%	$11.94+163.6%	$4.53+22.8%	$3.69+10.1%	$3.35+14.7%	$2.92+8.1%	$2.70-50.3%	$5.43
Diluted Shares (Avg)	N/A	360M+0.1%	360M+0.1%	360M+0.1%	359M+0.1%	359M+0.1%	359M+0.1%	358M+4.2%	344M+1.0%	340M+0.4%	339M+0.3%	338M+0.5%	336M+0.5%	334M+0.6%	332M-0.4%	334M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$1.7B+0.8%	$1.9B+14.5%	$1.6B+8.1%	$1.5B-3.0%	$1.7B+10.4%	$1.6B+10.4%	$1.5B+6.0%	$1.6B+18.4%
SG&A Expenses	$233.5M+5.4%	$223.0M+7.9%	$241.1M+9.2%	$237.6M+8.6%	$221.6M+8.3%	$206.7M+0.3%	$220.8M+3.7%	$218.8M+6.5%
Operating Income	$1.1B-2.0%	$1.3B+18.2%	$1.0B+7.7%	$972.6M-5.0%	$1.1B+12.9%	$1.1B+15.5%	$947.1M+9.7%	$1.0B+24.9%
EBITDA	$1.2B-1.8%	$1.4B+17.0%	$872.1M+8.7%	$1.1B-4.8%	$1.2B+11.8%	$1.2B+13.9%	$802.3M+12.0%	$1.1B+21.9%
Interest Expense	$43.6M-0.9%	$43.6M+4.6%	$43.7M+7.4%	$44.0M+9.5%	$44.0M+9.7%	$41.7M+4.5%	$40.7M+2.5%	$40.2M+1.5%
Income Tax	$285.9M-6.3%	$356.6M+23.6%	$395.5M+78.2%	$269.0M+1.9%	$305.2M+12.5%	$288.6M+11.8%	$222.0M+16.0%	$264.1M+17.8%
Net Income	$1.0B+1.6%	$1.2B+20.7%	$1.2B+35.3%	$908.0M-0.5%	$1.0B+16.1%	$956.2M+11.8%	$874.6M+7.4%	$912.8M+21.7%
EPS (Basic)	$2.89+2.8%	$3.25+23.6%	$3.25+35.4%	$2.49-0.8%	$2.81+15.6%	$2.63+11.9%	$2.40+7.1%	$2.51+21.8%
EPS (Diluted)	$2.88+2.5%	$3.18+21.4%	$3.24+35.0%	$2.49-0.4%	$2.81+16.1%	$2.62+11.5%	$2.40+7.1%	$2.50+21.4%
Diluted Shares (Avg)	361M+0.3%	363M+0.8%	N/A	360M+0.1%	360M+0.1%	360M+0.1%	N/A	360M+0.1%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses.

CME Balance Sheet

CME quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$198.4B+44.4%	$137.4B+6.0%	$129.7B-25.5%	$174.2B-11.5%	$196.8B+57.9%	$124.7B+65.7%	$75.2B-2.9%	$77.5B+2.2%	$75.8B+9.3%	$69.4B+3.0%	$67.4B-6.8%	$72.2B+33.1%	$54.3B+39.7%	$38.9B-4.7%	$40.8B
Current Assets	$165.4B+60.5%	$103.0B+8.6%	$94.9B-31.8%	$139.1B-14.0%	$161.8B+81.2%	$89.3B+125.6%	$39.6B-5.5%	$41.9B-10.7%	$46.9B+17.2%	$40.0B+5.6%	$37.9B-10.9%	$42.5B+74.3%	$24.4B+179.9%	$8.7B-20.4%	$10.9B
Cash & Equivalents	$4.4B+52.7%	$2.9B-0.7%	$2.9B+7.1%	$2.7B-4.0%	$2.8B+73.6%	$1.6B+5.3%	$1.6B+12.9%	$1.4B-27.8%	$1.9B+1.9%	$1.9B+10.4%	$1.7B+23.9%	$1.4B-44.7%	$2.5B+53.9%	$1.6B+54.0%	$1.0B
Short-Term Investments	$125.0M+10.4%	$113.2M+1.3%	$111.7M+16.4%	$96.0M-16.5%	$115.0M+14.0%	$100.9M+21.3%	$83.2M+14.1%	$72.9M-19.1%	$90.1M+8.2%	$83.3M+14.9%	$72.5M-2.9%	$74.7M+9.2%	$68.4M+20.8%	$56.6M+18.9%	$47.6M
Accounts Receivable	$639.2M+11.5%	$573.1M+7.0%	$535.6M+10.8%	$483.2M+11.2%	$434.5M-5.8%	$461.3M-6.2%	$491.8M-11.1%	$553.3M+53.8%	$359.7M-1.3%	$364.4M+1.8%	$357.8M+4.9%	$341.2M+12.7%	$302.7M+13.2%	$267.5M-7.6%	$289.4M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$10.5B+0.3%	$10.5B-0.1%	$10.5B+0.1%	$10.5B-0.4%	$10.5B-2.5%	$10.8B+0.5%	$10.7B-0.6%	$10.8B+42.8%	$7.6B0.0%	$7.6B0.0%	$7.6B0.0%	$7.6B0.0%	$7.6B0.0%	$7.6B-5.2%	$8.0B
Total Liabilities	$169.7B+52.9%	$111.0B+7.8%	$103.0B-30.1%	$147.3B-13.0%	$169.4B+72.3%	$98.3B+100.4%	$49.1B-4.8%	$51.5B-3.5%	$53.4B+8.9%	$49.0B+4.7%	$46.8B-8.8%	$51.3B+55.0%	$33.1B+90.8%	$17.4B-9.3%	$19.1B
Current Liabilities	$160.3B+56.7%	$102.3B+9.5%	$93.4B-32.2%	$137.7B-14.2%	$160.4B+81.9%	$88.2B+129.0%	$38.5B-6.7%	$41.3B-9.6%	$45.7B+17.3%	$38.9B+5.8%	$36.8B-11.3%	$41.5B+78.2%	$23.3B+206.0%	$7.6B-20.8%	$9.6B
Non-Current Liabilities	$9.4B+8.7%	$8.6B-9.5%	$9.6B-0.6%	$9.6B+7.0%	$9.0B-11.2%	$10.1B-4.0%	$10.5B+2.9%	$10.2B+32.8%	$7.7B-23.6%	$10.1B+1.0%	$10.0B+2.0%	$9.8B-0.2%	$9.8B+0.7%	$9.7B+2.3%	$9.5B
Total Equity	$28.7B+8.5%	$26.5B-0.9%	$26.7B-0.5%	$26.9B-1.9%	$27.4B+4.0%	$26.4B+0.7%	$26.2B+0.7%	$26.0B+15.9%	$22.4B+10.2%	$20.3B-1.0%	$20.6B-1.8%	$20.9B-1.1%	$21.2B-1.2%	$21.4B-0.6%	$21.6B
Retained Earnings	$6.4B+53.7%	$4.2B-6.0%	$4.5B-6.1%	$4.7B-7.9%	$5.2B+3.1%	$5.0B-0.3%	$5.0B+3.2%	$4.9B+8.0%	$4.5B+78.1%	$2.5B-13.2%	$2.9B-12.4%	$3.3B-5.1%	$3.5B-12.5%	$4.0B-7.7%	$4.3B

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$194.7B+8.2%	$202.0B+28.0%	$198.4B+44.4%	$187.1B+35.8%	$179.9B+45.8%	$157.8B+19.5%	$137.4B+6.0%	$137.8B+9.7%
Current Assets	$161.6B+11.1%	$169.0B+36.9%	$165.4B+60.5%	$152.8B+48.1%	$145.5B+63.9%	$123.4B+26.9%	$103.0B+8.6%	$103.1B+13.6%
Cash & Equivalents	$2.1B+8.2%	$2.4B+70.2%	$4.4B+52.7%	$2.4B+5.4%	$2.0B+10.7%	$1.4B-2.2%	$2.9B-0.7%	$2.3B+1.0%
Short-Term Investments	$131.4M+11.7%	$124.2M+9.0%	$125.0M+10.4%	$123.2M+9.7%	$117.6M-3.4%	$113.9M-5.9%	$113.2M+1.3%	$112.3M+7.9%
Accounts Receivable	$753.1M+12.8%	$935.5M+21.5%	$639.2M+11.5%	$642.9M+2.1%	$667.6M+11.4%	$770.2M+22.6%	$573.1M+7.0%	$629.4M+12.7%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$10.5B-0.2%	$10.5B+0.1%	$10.5B+0.3%	$10.5B0.0%	$10.5B+0.3%	$10.5B+0.1%	$10.5B-0.1%	$10.5B+0.3%
Total Liabilities	$168.2B+10.5%	$175.4B+34.1%	$169.7B+52.9%	$159.0B+45.1%	$152.2B+58.9%	$130.8B+24.7%	$111.0B+7.8%	$109.6B+12.5%
Current Liabilities	$158.7B+11.2%	$166.0B+36.7%	$160.3B+56.7%	$149.6B+48.4%	$142.8B+64.2%	$121.4B+26.3%	$102.3B+9.5%	$100.8B+14.7%
Non-Current Liabilities	$9.4B+0.7%	$9.4B0.0%	$9.4B+8.7%	$9.4B+7.0%	$9.4B+6.9%	$9.4B+6.6%	$8.6B-9.5%	$8.8B-8.5%
Total Equity	$26.5B-4.4%	$26.6B-1.5%	$28.7B+8.5%	$28.2B-0.1%	$27.7B+0.4%	$27.0B-0.5%	$26.5B-0.9%	$28.2B+0.2%
Retained Earnings	$5.5B+3.9%	$4.9B+4.2%	$6.4B+53.7%	$5.7B-2.4%	$5.3B-1.9%	$4.7B-4.2%	$4.2B-6.0%	$5.8B-1.8%

Not reported in any period shown, so not listed: Inventory, Long-Term Debt.

CME Cash Flow Statement

CME quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$4.3B	$4.3B+15.9%	$3.7B+6.9%	$3.5B+13.0%	$3.1B+27.2%	$2.4B-11.5%	$2.7B+1.6%	$2.7B+9.5%	$2.4B+39.4%	$1.8B+1.1%	$1.7B+13.0%	$1.5B+18.7%	$1.3B+0.9%	$1.3B+5.0%	$1.2B-9.4%	$1.3B
Depreciation & Amortization	N/A	$107.5M-6.6%	$115.1M-8.7%	$126.0M-6.6%	$134.9M-8.7%	$147.8M-3.5%	$153.2M-3.4%	$158.6M+33.6%	$118.7M+5.0%	$113.0M-12.5%	$129.2M0.0%	$129.2M-2.6%	$132.6M-1.9%	$135.1M-1.3%	$136.9M+6.5%	$128.5M
Stock-Based Compensation	N/A	$94.8M+5.9%	$89.5M+8.0%	$82.9M-1.7%	$84.3M+12.1%	$75.2M-21.7%	$96.0M+31.3%	$73.1M-24.2%	$96.5M+66.4%	$58.0M-12.4%	$66.2M+8.9%	$60.8M+10.9%	$54.8M+0.7%	$54.4M-11.4%	$61.4M+19.7%	$51.3M
Capital Expenditures	$96.3M	$83.5M-11.2%	$94.0M+23.0%	$76.4M-14.8%	$89.7M-29.5%	$127.2M-35.6%	$197.5M-19.6%	$245.6M+110.5%	$116.7M+42.5%	$81.9M-10.8%	$91.8M-19.6%	$114.2M-18.8%	$140.7M+12.0%	$125.6M-11.4%	$141.8M-17.7%	$172.2M
Free Cash Flow	$4.2B	$4.2B+16.6%	$3.6B+6.5%	$3.4B+13.9%	$3.0B+30.4%	$2.3B-9.6%	$2.5B+3.7%	$2.4B+4.4%	$2.3B+39.2%	$1.7B+1.8%	$1.6B+15.6%	$1.4B+23.3%	$1.2B-0.4%	$1.2B+7.1%	$1.1B-8.2%	$1.2B
Investing Cash Flow	$1.5B	$1.5B+1914.5%	-$82.6M-495.2%	$20.9M+104.3%	-$489.8M-938.7%	$58.4M+133.3%	-$175.5M-15.0%	-$152.6M+91.9%	-$1.9B-1150.4%	$179.9M+235.0%	$53.7M+200.0%	$17.9M+109.0%	-$199.1M-204.5%	$190.5M+191.2%	-$208.9M-36.0%	-$153.6M
Financing Cash Flow	$10.3B	$56.5B+1013.2%	$5.1B+110.5%	-$48.3B-90.4%	-$25.4B-136.3%	$69.9B+48.0%	$47.2B+2118.4%	-$2.3B-116.7%	-$1.1B+45.6%	-$2.0B-22.5%	-$1.6B-32.4%	-$1.2B+44.3%	-$2.2B-262.4%	-$606.0M-35.1%	-$448.4M+55.4%	-$1.0B
Dividends Paid	$4.1B	$3.9B+9.7%	$3.6B+10.8%	$3.2B+22.9%	$2.6B+20.3%	$2.2B+3.8%	$2.1B+24.4%	$1.7B-21.1%	$2.1B+7.8%	$2.0B+11.5%	$1.8B+33.0%	$1.3B-10.2%	$1.5B+149.8%	$599.1M-51.1%	$1.2B+228.4%	$372.8M
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0-100.0%	$220.4M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$947.1M-10.5%	$1.3B+12.8%	$1.1B+11.4%	$968.1M-3.5%	$1.1B+36.2%	$1.1B+25.1%	$1.0B-2.5%	$1.0B+17.1%
Depreciation & Amortization	$86.3M+0.9%	$85.5M+0.9%	-$147.5M-1.9%	$84.8M-1.5%	$85.5M-0.9%	$84.7M-3.2%	-$144.8M+1.4%	$86.1M-4.9%
Stock-Based Compensation	N/A	$21.8M+2.8%	N/A	N/A	N/A	$21.2M-9.0%	N/A	N/A
Capital Expenditures	$23.6M+28.3%	$21.8M+53.5%	$32.5M+24.0%	$18.4M-38.3%	$18.4M+1.1%	$14.2M-28.3%	$26.2M+26.0%	$29.8M+49.7%
Free Cash Flow	$923.5M-11.2%	$1.2B+12.3%	$1.1B+11.1%	$949.7M-2.4%	$1.0B+37.1%	$1.1B+26.3%	$991.7M-3.1%	$973.2M+16.3%
Investing Cash Flow	-$29.4M-63.3%	-$23.0M-43.8%	$1.6B+6234.0%	-$19.1M+35.3%	-$18.0M-260.0%	-$16.0M+29.8%	-$25.3M-24.0%	-$29.5M-51.3%
Financing Cash Flow	-$8.1B-138.5%	$2.1B-89.0%	$9.9B+1105.9%	$6.4B-52.1%	$21.0B+327.7%	$19.2B+892.1%	-$984.1M-138.0%	$13.3B+150.4%
Dividends Paid	$468.1M+2.8%	$2.7B+5.1%	$455.0M+8.6%	$455.3M+8.8%	$455.3M+8.8%	$2.6B+10.3%	$418.8M+4.7%	$418.5M+4.6%

Not reported in any period shown, so not listed: Share Buybacks.

CME Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CME quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Margin	64.9%+0.7pp	64.1%+2.5pp	61.6%+1.5pp	60.1%+3.7pp	56.4%+2.4pp	54.0%+0.9pp	53.2%-7.4pp	60.5%-2.9pp	63.4%+2.2pp	61.2%+1.4pp	59.8%+3.0pp	56.8%+1.1pp	55.8%-2.3pp	58.1%-3.6pp	61.6%
Net Margin	62.5%+4.9pp	57.5%-0.3pp	57.8%+4.2pp	53.6%-2.6pp	56.2%+13.1pp	43.1%-0.4pp	43.5%-2.0pp	45.5%	111.5%	42.7%+5.2pp	37.5%+1.3pp	36.2%+2.9pp	33.3%+2.5pp	30.8%-24.5pp	55.2%
Return on Equity	14.2%+0.9pp	13.3%+1.2pp	12.1%+2.1pp	10.0%+0.4pp	9.6%+1.6pp	8.0%-0.1pp	8.1%+0.5pp	7.6%-10.6pp	18.1%+10.6pp	7.5%+1.5pp	6.1%+0.7pp	5.4%+0.8pp	4.6%+0.4pp	4.2%-4.2pp	8.4%
Return on Assets	2.1%-0.5pp	2.6%+0.1pp	2.5%+0.9pp	1.5%+0.2pp	1.3%-0.3pp	1.7%-1.1pp	2.8%+0.3pp	2.5%-2.8pp	5.4%+3.1pp	2.2%+0.4pp	1.8%+0.3pp	1.6%-0.2pp	1.8%-0.5pp	2.3%-2.1pp	4.5%
Current Ratio	1.030.0x	1.010.0x	1.020.0x	1.010.0x	1.010.0x	1.010.0x	1.030.0x	1.010.0x	1.030.0x	1.030.0x	1.030.0x	1.020.0x	1.05-0.1x	1.140.0x	1.14
Debt-to-Equity	5.91+1.7x	4.19+0.3x	3.85-1.6x	5.48-0.7x	6.18+2.5x	3.73+1.9x	1.88-0.1x	1.98-0.4x	2.380.0x	2.41+0.1x	2.28-0.2x	2.45+0.9x	1.57+0.8x	0.81-0.1x	0.89
Asset Turnover	0.030.0x	0.040.0x	0.040.0x	0.030.0x	0.020.0x	0.040.0x	0.060.0x	0.060.0x	0.050.0x	0.050.0x	0.050.0x	0.040.0x	0.050.0x	0.070.0x	0.08
FCF Margin	64.3%+5.6pp	58.7%-1.9pp	60.5%+1.4pp	59.1%+10.6pp	48.5%-3.0pp	51.6%+1.7pp	49.9%-4.1pp	53.9%+8.1pp	45.8%+0.2pp	45.6%+3.0pp	42.6%+5.7pp	37.0%-2.4pp	39.3%+2.3pp	37.0%+1.2pp	35.8%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Margin	64.9%-1.8pp	69.7%+2.2pp	61.8%-0.3pp	63.2%-1.4pp	66.7%+1.4pp	67.5%+3.0pp	62.1%+2.1pp	64.6%+3.3pp
Net Margin	61.1%+0.5pp	61.4%+3.2pp	71.8%+14.4pp	59.1%+1.4pp	60.6%+3.0pp	58.2%+0.7pp	57.3%+0.8pp	57.6%+1.5pp
Return on Equity	3.9%+0.2pp	4.3%+0.8pp	4.1%+0.8pp	3.2%0.0pp	3.7%+0.5pp	3.5%+0.4pp	3.3%+0.3pp	3.2%+0.6pp
Return on Assets	0.5%0.0pp	0.6%0.0pp	0.6%0.0pp	0.5%-0.2pp	0.6%-0.1pp	0.6%0.0pp	0.6%0.0pp	0.7%+0.1pp
Current Ratio	1.020.0x	1.020.0x	1.030.0x	1.020.0x	1.020.0x	1.020.0x	1.010.0x	1.020.0x
Debt-to-Equity	6.34+0.9x	6.59+1.7x	5.91+1.7x	5.64+1.8x	5.49+2.0x	4.84+1.0x	4.19+0.3x	3.88+0.4x
Asset Turnover	0.010.0x	0.010.0x	0.010.0x	0.010.0x	0.010.0x	0.010.0x	0.010.0x	0.010.0x
FCF Margin	54.1%-7.3pp	65.8%-1.3pp	66.8%+1.8pp	61.8%+0.4pp	61.5%+12.0pp	67.1%+8.5pp	65.0%-6.1pp	61.4%-1.1pp

Not reported in any period shown, so not listed: Gross Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
CME Group Inc. CME	FY2025	$6.5B	$4.1B	62.5%	$100.9B	60/100
Intercontinental Exchange Inc. ICE	FY2025	$12.6B	$3.3B	26.2%	$87.7B	63/100
Moody's Corporation MCO	FY2025	$7.7B	$2.5B	31.9%	$80.4B	75/100
Coinbase Global, Inc. COIN	FY2025	$7.2B	$1.3B	18.1%	$47.3B	61/100
S&P Global Inc. SPGI	FY2025	$15.3B	$4.5B	29.1%	$120.2B	61/100
Nasdaq, Inc. NDAQ	FY2025	$8.3B	$1.8B	21.6%	$52.3B	61/100

Where CME Group Inc. Ranks

Frequently Asked Questions

What is CME Group Inc.'s annual revenue?

CME Group Inc. (CME) reported $6.5B in total revenue for fiscal year 2025. This represents a 6.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is CME Group Inc.'s revenue growing?

CME Group Inc. (CME) revenue grew by 6.4% year-over-year, from $6.1B to $6.5B in fiscal year 2025.

Is CME Group Inc. profitable?

Yes, CME Group Inc. (CME) reported a net income of $4.1B in fiscal year 2025, with a net profit margin of 62.5%.

What is CME Group Inc.'s EBITDA?

CME Group Inc. (CME) had EBITDA of $4.3B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is CME Group Inc.'s operating margin?

CME Group Inc. (CME) had an operating margin of 64.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is CME Group Inc.'s net profit margin?

CME Group Inc. (CME) had a net profit margin of 62.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Does CME Group Inc. pay dividends?

Yes, CME Group Inc. (CME) paid $5.00 per share in dividends during fiscal year 2025.

What is CME Group Inc.'s return on equity (ROE)?

CME Group Inc. (CME) has a return on equity of 14.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is CME Group Inc.'s free cash flow?

CME Group Inc. (CME) generated $4.2B in free cash flow during fiscal year 2025. This represents a 16.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is CME Group Inc.'s operating cash flow?

CME Group Inc. (CME) generated $4.3B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are CME Group Inc.'s total assets?

CME Group Inc. (CME) had $198.4B in total assets as of fiscal year 2025, including both current and long-term assets.

What are CME Group Inc.'s capital expenditures?

CME Group Inc. (CME) invested $83.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

What is CME Group Inc.'s current ratio?

CME Group Inc. (CME) had a current ratio of 1.03 as of fiscal year 2025, which is considered adequate.

What is CME Group Inc.'s debt-to-equity ratio?

CME Group Inc. (CME) had a debt-to-equity ratio of 5.91 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is CME Group Inc.'s return on assets (ROA)?

CME Group Inc. (CME) had a return on assets of 2.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is CME Group Inc.'s P/E ratio?

CME Group Inc. (CME) trades at 23.5x earnings, its market capitalization divided by net income of $4.3B net income, trailing 12 months to June 30, 2026. The market capitalization is $100.9B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is CME Group Inc.'s price-to-sales ratio?

CME Group Inc. (CME) trades at 14.9x sales, its market capitalization divided by revenue of $6.8B revenue, trailing 12 months to June 30, 2026. The market capitalization is $100.9B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is CME Group Inc.'s Altman Z-Score?

CME Group Inc. (CME) has an Altman Z-Score of 0.54, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is CME Group Inc.'s Piotroski F-Score?

CME Group Inc. (CME) has a Piotroski F-Score of 4 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are CME Group Inc.'s earnings high quality?

CME Group Inc. (CME) has an earnings quality ratio of 1.05x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can CME Group Inc. cover its interest payments?

CME Group Inc. (CME) has an interest coverage ratio of 24.39x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is CME Group Inc.?

CME Group Inc. (CME) scores 60 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.